Palbociclib
Adult Central Nervous System Germ Cell Tumor
Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Abramson Cancer Center at Penn Medicine
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01037790CT.gov Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Adult Central Nervous System Germ Cell Tumor
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Palbociclib (this asset) | Abramson Cancer Center at Penn Medicine | P2 | CCC · 55 |
| Palifosfamide-Tris | Indiana University | P2 | CCC |
| Melphalan | City of Hope Medical Center | P1 | CC |
| Nogitecan | City of Hope Medical Center | P1 | CC |
| Nivestim | City of Hope Medical Center | P1 | CC |
| Busulfanum | City of Hope Medical Center | P1 | CC |
| EF-5 | National Cancer Institute (NCI) | P1 | C |
Other indications for Palbociclib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P4 | BB · 71 |
| Her2-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Hormone Receptor-Positive Breast Cancer | — | P3 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Palbociclib in Adult Central Nervous System Germ Cell Tumor. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/palbociclib-adult-central-nervous-system-germ-cell-tumor
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →